The metabolic state of T cells strongly influences their effector function and anti-tumor efficacy. St. Paul et al. (2021) report that Tc22, a CD8+ T cell subset with potent anti-tumor activity, upregulates the pantothenate/coenzyme A (CoA) pathway and that treatment with CoA or pantothenate is sufficient to enhance tumor immunotherapy.
|Original language||English (US)|
|Number of pages||2|
|State||Published - Dec 7 2021|
Bibliographical notePublisher Copyright:
© 2021 Elsevier Inc.
PubMed: MeSH publication types
- Journal Article